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trends in transmitted HIV drug resistance:
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Abstract
Background: HIV transmitted drug resistance (TDR) surveillance is usually conducted by sampling from a large
population. However, overall TDR prevalence results may be inaccurate for many individual clinical setting. We
analyzed HIV genotypes at a tertiary care setting in Ottawa, Ontario in order to evaluate local TDR patterns among
sub-populations.
Method: Genotyping reports were digitized from ART naïve patients followed at the Immunodeficiency Clinic at the
Ottawa Hospital, between 2008 and 2010. Quality controlled, digitized sequence data were assessed for TDR using the
Stanford HIV Database. Patient characteristics were analyzed according to TDR patterns. Finally, a phylogenetic tree was
constructed to elucidate the observed pattern of HIV TDR.
Results: Among the 155 clinic patients there was no statistically significantly difference in demographics as compared
to the Ontario provincial HIV population. The clinic prevalence of TDR was 12.3%; however, in contrast to the data from
Ontario, TDR patterns were inverted with a 21% prevalence among MSM and 5.5% among IDU. Furthermore, nearly
80% of the observed TDR was a D67N/K219Q pattern with 87% of these infections arising from a distinct phylogenetic
cluster.
Conclusions: Local patterns of TDR were distinct to what had been observed provincially. Phylogenetic analysis
uncovered a cluster of related infections among MSM that appeared more likely to be recent infections. Results
support a paradigm of routine local TDR surveillance to identify the sub-populations under care. Furthermore, the
routine application of phylogenetic analysis in the TDR surveillance context provides insights into how best to
target prevention strategies; and how to correctly measure outcomes.
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Background
HIV drug resistance (DR) compromises successful
clinical outcomes in both treatment naïve and treatment
experienced patients [1,2]. In the context of emergent
HIV therapy such as occupational exposure, occult HIV
DR may lead to failure of post-exposure prophylaxis [3,4].
For these reasons and also for the purposes of mapping
the epidemic, population level surveillance of transmitted
DR (TDR) remains important [5,6]; however, inherent
in population analyses of TDR is the loss of resolution
at the local level. True local HIV TDR prevalence is
obscured through estimates based on larger data sets
generated at the regional or national levels. For example, if
two clinics with highly divergent HIV TDR prevalence’s
are sampled, then when analyzed in aggregate, the average
prevalence is inaccurate for both clinics. With new
interventions such as treatment as prevention being
considered, accurate local TDR data is critical for program
implementation and for outcome measures.
HIV TDR was evaluated among anti-retroviral (ART)
naïve patients referred over a period of 3 years to the
Immunodeficiency Clinic in the 2nd largest city in Ontario,
Canada. The Ottawa Hospital Immunodeficiency Clinic
routinely carries out baseline HIV DR testing [7-9] which
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provided access to the genetic sequence of the virus from
the clinical HIV genotype report. Using this information
we re-interpreted the HIV genotype in order to determine
the local TDR trends and analyzed the distribution of




Clinical and demographic data were obtained via chart
review for all treatment-naive HIV patients referred to
the Ottawa Hospital Immunodeficiency Clinic from
August 2007 until June 2010. Variables extracted from
the chart included: date of birth, country of origin, date
of initial HIV diagnosis, likely HIV exposure category
likely date of infection according to recall, earliest
available CD4 count, viral load, and history of previous
anti-retroviral drug (ART) exposure. Exposure category
for HIV infection was hierarchically categorized as follows:
men who have sex with men (MSM), intravenous drug
use (IDU), HIV endemic country, heterosexual contact,
and other. Data were entered into a database that was
then anonymized for analysis through the assigning of
a random study number. Blood specimens were taken
as part of standard care. This study was approved by
the Ottawa Hospital Research Ethics Board.
HIV genotyping
Plasma was separated from EDTA anticoagulated blood
within 4 hours of collection and frozen at -80°C. Frozen
plasma was shipped to the HIV Drug Resistance Testing
Program at the BC Centre for Excellence in HIV/AIDS,
Vancouver, British Columbia for genotyping. Hard copy
Vircotype clinical HIV drug resistance reports that
included the HIV pol sequence submitted for inter-
pretation were returned to the clinician and placed on
the chart.
Digitization of nucleotide sequences
Nucleotide sequences from the Vircotype reports were
digitized using Readiris Pro 11 optical character recog-
nition (OCR) software (Iris Technologies, Delray Beach,
Florida, USA). Digitized sequences were aligned and
scanning errors corrected. To verify the fidelity of the
scanning software, 10 digitized sequences were chosen
at random and twice manually compared to the original
Vircotype hard copies.
Genotypic resistance analysis
155 quality controlled sequences were submitted in
FASTA format to the Stanford HIV Database Calibrated
Population Resistance tool (CPR) [10] in order to derive
an unambiguous and stable measure of TDR [11].
TDR mutations were identified using the World Health
Organization (WHO) surveillance drug resistance mutation
list [12]. Integral quality control assessment of the CPR
analysis revealed 12 further sequences with non-IUPAC
letter codes that were corrected and those sequences
were re-submitted.
Phylogenetic analysis
Genotype sequences were edited, and aligned using
Muscle [13], then trimmed to identical lengths (986 bp)
within Geneious 5.4.3 [14]. 136 reference pol sequences
from the Los Alamos HIV Sequence database [15] and
119 pol sequences from the Canadian national HIV
drug resistance surveillance were aligned and trimmed
as above. Codons that harboured TDR mutations iden-
tified in the CPR analysis were stripped from all of the
sequences within the alignment in order to minimize
convergent evolution artefact. A maximum likelihood
tree was constructed using the general time reversible
(GTR) model in PHYML [16] in order to determine
phylogenetic interrelationships among viral sequences.
Robustness of relationships among sequences was
evaluated using bootstrap analysis with 100 replicates.
Clusters having bootstrap values >98% and within
cluster branch lengths of less than 0.04 were further
evaluated [17]. The similarity of sequences within clusters
was compared to background subtype B sequences using
mean pair-wise distance within a Maximum Composite
Likelihood model with pair-wise deletion [18].
Statistical analysis
303 patients were referred to the Ottawa Hospital
Immunodeficiency clinic between August 2007 and
June 2010 for assessment and care of their HIV infec-
tion. 196 patients (65%) were ART naïve of which 162
had undergone baseline genotyping. 155 of the base-
line genotype reports were successfully digitized and
used in the subsequent analysis. Reasons for the unavail-
ability of a genotype were: insufficient plasma (13); geno-
typing was performed elsewhere (10); viral load was too
low (9); or genotype not ordered (2).
Statistical analysis was performed using EpiInfo 2000
[19]. Descriptive statistics included frequency analysis
(percentages) for categorical variables and means for
normally distributed continuous variables. To compare
the means of the continuous data an unpaired t-test
was used. Chi-square or Fisher’s exact probability tests
were used for categorical data. To determine whether
the HIV infected patients seen at the Ottawa Hospital
clinic patients were similar to those seen in the province
as whole, comparisons of the characteristics of our cohort
were compared with those from all reported Ontario
provincial HIV cases [20]. To evaluate the internal validity
of the cohort, characteristics of patients with genotyping
results were compared with those from all patients seen
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concurrently in the clinic. Odds Ratios (OR) and 95%
Confidence Intervals (CI) were calculated. P-values less
than 0.05 were regarded as statistically significant.




155 sequences from ART naïve subjects were analyzed.
Of the 155 patients for whom diagnosis date was recorded
(n=145), 75% were genotyped within 1 year of diagnosis.
The mean elapsed time from patient’s recollection of
diagnosis date, to genotype was 487 days, with a median
of 56 days (IQR 234 days).
Representativeness of the data
Epidemiologic characteristics of the 155 study cohort
patients, for whom a genotype sequence was available,
were compared with those from cases in the Report on
HIV/AIDS in Ontario 2008 [20] and also to other
clinic patients. There was no significant difference with
respect to age at diagnosis, gender or risk factor for
acquisition of HIV (Table 1) between either the study
cohort or the patients in the clinic. Similarly, when
compared to all other clinic patients, there were no
significant differences among characteristics of patients
for whom genotyping results were available.
The mean age of patients in the study cohort was 37
years (median 36 years IQR (31, 44)) with 75% being
male. The most commonly reported risk categories for
HIV acquisition were MSM followed by birth in an HIV
endemic country, with each accounting for approximately
1/3 of the group. Analyzed by gender, 58% of the men
reported MSM as their risk factor for HIV infection,
while heterosexual contact was the dominant risk factor
among women (86%). The study cohort had an mean
viral load of 4.17 log10 copies/ml (median 4.26 log10
copies/ml, IQR (3.67,4.72)). The mean CD4 count was
332 cells/ul (median 303.0 cells/ul IQR (149.5,473.5)).
Sixty-eight percent of the study cohort was infected
with subtype B virus with the next most common subtype
being subtype C (23%).
Drug resistance
Of the 155 ART-naïve subjects with digitized HIV pol se-
quence that were subjected to further analysis, OCR fidelity
validation trials identified only 2 incorrect base identification
errors out of 11,600 bases analyzed (99.98% concordance).
Neither of these errors influenced the TDR interpretation.
The crude prevalence of any drug resistance for the
period of 2007-2010 was 12.3%. Although the TDR
prevalence appeared to increase over the study period
this trend was not significant (Chi-square, p=0.65).
Fifteen of the 19 cases of TDR were resistant to NRTIs
Table 1 Comparison of HIV epidemiologic characteristics of study patients with provincial surveillance report
Ontario1 Ottawa1 Clinic Cohort (n=196) Clinic Cohort with Genotyping (n=155)
No. % No. % No. % No. %
Gender
M 7134 74.7 116 70.3 141 71.9 115 74.2
F 2411 25.3 49 29.7 55 28.1 40 25.8
Age at diagnosis
0-19 634 2.1 N/A N/A 6 3.1 5 3.2
20-29 7053 23.7 N/A N/A 41 20.9 31 20.0
30-39 11251 37.8 N/A N/A 73 37.2 61 39.4
40-49 6046 20.3 N/A N/A 49 25.0 40 25.8
50< 2430 8.2 N/A N/A 26 13.3 18 11.6
Unclear 2373 8 N/A N/A 1 0.5 0 0.0
Exposure category
MSM 4391 45.1 56 34.1 76 38.8 61 39.4
IDU 715 7.3 22 13.4 24 12.2 18 11.6
MSM/IDU 248 2.5 4 2.4 3 1.5 2 1.3
HIV-endemic 2236 23.0 54 32.9 44 22.4 34 21.9
Heterosexual 1825 18.7 25 15.2 44 22.1 35 22.6
Other 327 3.4 3 1.8 1 0.5 1 0.6
Unclear 0 0.0 0 0 4 2.0 4 2.6
N/A information not provided.
1Source: 2008 Report on HIV/AIDS in Ontario, Ontario HIV Epidemiologic Monitor Unit.
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only. Two patients had 2-class resistance with one having a
combination of NNRT/NRTI resistance and the other pa-
tient exhibiting combined NRTI/PI resistance. One patient
had resistance to all 3 classes of ART. Details of the patterns
of TDR for each patient can be found in Table 2.
TDR was not evenly distributed within the sub-
populations of the study cohort. Although 30% of the
infections were non-B subtype, the prevalence of TDR
was only 2% as compared to 17% among subtype-B
infections. In addition, the prevalence of TDR among
women was 2.5% versus 16% among the men. Consistent
with the gender based distribution of drug resistance,
the TDR prevalence was 21% in MSM and only 5.5%
among IDU. Finally, there was a trend towards increased
rates of TDR among patients who had genotyping
within 6 month after diagnosis (Table 3).
Phylogenetic analysis
The most common pattern of drug resistance mutations
seen was the combination of RT mutations D67N and
K219Q conferring low-level resistance to AZT. In fact,
15 of the 19 drug resistant specimens collected over the
three-year period contained this identical dug resistance
pattern (Table 2) which warranted further investigation.
A phylogenetic analysis using a GTR model in PHYML,
established that 13 out of the 15 sequences containing
the D67N/K219Q formed a distinct out-group with a
bootstrap value of 100% (Figure 1). The monophyletic
cluster possessed a within cluster pair-wise distance of
less than 1%, compared with the background variation
of 6%, which is consistent with HIV transmission over
a shorter period of time. There were two additional
D67N/K219Q containing sequences that were not
found to be part of this cluster. These two sequences
were not related to each other. 17 additional clusters
were found within this cohort with most (60%) having
only two members. There were 4 clusters with 3 members
and 3 clusters with 4 members. No TDR was found within
any of these other clusters (Figure 1).
The phylogenetically inferred relationships are strongly
supported by the observed epidemiological characteristics.
All of the patients with the D67N/K219Q resistance
pattern are male, are infected with a clade B virus and
either have MSM as their risk factor for acquisition or
it is not reported (2 cases). These characteristics were
significantly associated with this group (all OR > 6 and
all p-values <0.02) when compared to all other genotyped
patients. All but one of the cases with D67N/K219Q
were less than 6 months induration, however the small
numbers in the study prevented the correlation with recent
infections being significant. The relationship between the
pattern of clustering observed on the phylogenetic tree and
the characterization of a clearly defined sub-population
supports the interpretation of cluster identification as
means to identify a group at risk of HIV infection.
Discussion
HIV TDR Surveillance projects are typically designed
to avoid sample bias by seeking out an ever enlarging
(n) [5,21,22]. Paradoxically, the most relevant information
for the clinician arrives from a biased but more relevant,
local sample. Similar to other national surveillance
projects, [23] ideal HIV TDR data should be systematically
obtained at the local level, where it most accurately reflects
the ecology of the virus, and then collated at a regional
level. This approach would produce clinically relevant
data and facilitate the population level study of HIV
TDR dynamics [24,25]. This study is unique in that it
compares the local viral HIV TDR landscape with that
predicted to be present in a large population based
study [26]. While the cohort of patients in this analysis
was not significantly different with respect to age, gender,
risk factors or ethnicity from the HIV infected population
in Ontario; there were striking differences in the TDR
distribution within our clinic sub-populations when
compared to the province as a whole.
Initially appearing to be consistent with results from
other groups [17,27-33], the average prevalence of TDR
at 12.3% is heterogeneously distributed. TDR prevalence
Table 2 Surveillance drug resistance mutations patterns
for patients
TDR Mutations
Patient NRTI NNRTI PI
1 D67N, K219Q
2 D67N, K219Q
3 K65KR, D67N, K219Q
4 K103N
5 D67N, K219Q














Prevalence of each TDR mutation among the 155 specimens were: D67N
(10.3%), K219Q (9.7%), K103N (1.9%), K70R (1.3%), with all others at 0.6%.
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is lower in women, people with non subtype-B infections
and acquisition of HIV through non-MSM contact [33,34].
However, in our cohort 1 in 5 patients who acquired
their infection through sex with men harboured some
form of TDR, almost double the average prevalence.
More striking is that most recent available data from
on Ontario-wide study revealed that TDR prevalences
were three-fold higher among intravenous drug users
(IDU) than among MSM [26]. Despite our clinic cohort
appearing to be representative of the population of the
Table 3 Comparison of patient characteristics between those with and without drug resistance
Characteristic Patients with TDR Patients without TDR OR (95% CI) p-value
Number (%) Number (%)
N=19 N=136
Country of Birth
Canada 12 (63.2%) 79 (58.1%)
1.44 (0.47, 4.62) 0.48
Other 7 (36.8%) 57 (41.9%)
Gender
Male 18 (94.7%) 97 (71.3%)
7.18 (1.06, 309.13) 0.03
Female 1 (5.3%) 39 (28.7%)
Mean age (range) 38 (23-49) 37 (18-70) 0.73
Exposure Category
MSM 13 (68.4%) 48 (35.3%)
IDU 1 (5.3%) 17 (12.5%)
MSM/IDU 1 (5.3%) 1 (0.7%)
HIV endemic 2 (10.5%) 32 (23.5%)
Heterosexual 0 35 (25.7%)
Other 0 1 (0.7%)
Unknown 2 (10.5%) 2 (1.5%)
MSM 13 (68.4%) 48 (35.3%)
3.97 (1.30, 12.63) 0.005
All other 6 (31.6%) 88 (64.7%)
Clade
B 18(94.7%) 88 (64.7%)
9.73 (1.45,417.43) 0.009
Non-B 1 (5.3%) 48 (35.3%)
CD4 Count
<200 6 (31.6%) 41 (30.1%)
0.97
200-500 8 (42.1%) 64 (47.1%)
>500 5 (26.3%) 29 (21.3%)
Unknown 0 2 (1.5%)
Viral Load
<5,000 5 (21.1%) 36 (27.2%)
0.37
5,000-10,000 3 (15.8%) 13 (9.6%)
10,000-100,000 8 (47.4%) 57 (41.2%)
>100,000 2 (10.5%) 29 (21.3%)
Unknown 1 (5.3%) 1 (0.7%)
Time Between Diagnosis and Genotype
0.07*
<6 months 17 (89.5%) 88 (64.7%)
6-12 months 0 7 (5.1%)
>12 months 1 (5.3%) 34 (25.5%)
Unknown 1 (5.3%) 7 (5.1%)
* Unknowns removed from analysis.
* “Zero” cell adjustments made in calculations.
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province as whole, we observed the exact opposite pattern
of TDR with MSM having four times the prevalence of
TDR than was found among IDU. The distinct and
contrasting TDR distribution observed among our clinic
sub-populations was lost completely when data was
analyzed at the provincial level highlighting the importance
of local analysis of TDR patterns.
One of the significant drivers of the distribution of TDR,
within our local sub-populations, was the cluster of related
infections. Comparing the group of patients with the
D67N/K219Q (n=15) with those patients with another pat-
tern of TDR (n=4), it is clear that the epidemiologic charac-
teristics of patients with TDR in our clinic were made up of
those from this larger group. The D67N/K219Q combin-
ation has a low fitness cost to the virus, is durable in the re-
cipient after infection, is readily transmitted and serves as
an excellent marker for TDR [35]. The similar pattern of
drug resistance found in more than three quarters of the re-
sistant cases, cued the molecular epidemiology investigation
that identified the cluster of related infections among
MSM. However, in the absence of this TDR marker, a clus-
ter of related viruses would go unrecognized and, along
with that, the opportunity to recognize an outbreak.
Phylogenetics are often applied to large data sets to illu-
minate transmission patterns or trends in drug resistance
at the population level [36-42]. Our findings continue to
support the value in applying routine phylogenetics at the
clinical level to uncover related infections even in the ab-
sence of common patterns of TDR [41,42].
While having clinical implications, there is potential
public health benefit in identifying a cluster of HIV
transmission [43]. Although the limitations of phylogenetic
analysis include the inability to attribute directionality of a
transmission event [44,45], highly related viral sequences
may correlate with shared social or risk-behaviour patterns
[46]. If a cluster of related infections goes unrecognized
by public health, an opportunity may be lost to mitigate
ongoing transmission; especially originating from those
individuals recently infected or from those not yet diag-
nosed. Public health education within the communities
in which higher HIV TDR is found, more frequent testing
of those within those communities and appropriate and
early treatment are all public health interventions can
reduce transmission and improve the outcomes within
that community. From the outcome perspective, it
is extremely important to understand the reasons for
Figure 1 Maximum likelihood tree of HIV pol sequences generated using GTR model in PHYML with 100 bootstrap replicates.
Sequences were trimmed to 986 bp with identified TDR mutation codons removed. 155 study cohort sequences are present in a background of
255 sequences further described in the methods. Orange box shows the D67N/K219Q cluster that was identified. For comparison purposes
another cluster identified in the study cohort is identified in blue. ** Indicates the out-group N sequence N.CM.97.YBF106.
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successes and failures of public health interventions.
An occult transmission cluster, reflecting a negative
result such as incident infection or drug resistance,
can negatively bias the interpretation of a program that is
actually effective. Studies are underway to examine how
best to balance the use of phylogenetics in public
health investigations with individual privacy [47].
There are some limitations to be considered in this
study. Nearly 90% of the specimens that contained drug
resistance were obtained less than 6 months after diagnosis
while only 63% of the specimens without TDR were
collected in the same timeframe. While our evaluation
of TDR may be biased toward identifying less durable
mutations the D67N/K219Q, which represented the
majority of our TDR, has a low fitness cost and should
be durable. The over-representation of these mutations
among those recently diagnosed is likely consistent
with the mutations acting as a marker for recent cluster
formation. While we were diligent in identifying all
new patients seen at the largest HIV referral center in
Ottawa, there is the possibility of sample bias due to
the unavailability of genotypes from some patients.
Consequently, even though our cohort appears to be
statistically representative of the epidemic in Ontario, our
findings on TDR are valid only for the sub-populations
seen at the Ottawa Hospital. This sample bias may
also affect the depth of sampling in the phylogenetic
analysis resulting in the possibility that the clustering
of the D69N/K219Q mutations among MSM may be
more widespread. Although our study possesses the
theoretical limitations associated with sample bias, it
is precisely these “limitations” that exposed the divergent
TDR trends among our clinic sub-populations. Indeed,
similar disparities in DR surveillance patterns have
been observed in bacterial infections resulting in a
similar call for local surveillance [48].
Conclusion
We have shown that analysis of HIV genotypes, at the local
level, reveals patterns of DR that are distinct from those
described in surveillance reports encompassing larger geo-
graphic areas. Local molecular epidemiological analysis of
these genotypes may provide insight into the reasons why
these HIV DR patterns differ and expose occult infection
clusters. Using the model for antibiotic resistance surveil-
lance, collecting and analyzing HIV TDR data at the clinic
level and then collating these results at provincial and
national levels would both optimize patient care and pro-
vide more complete surveillance [23]. Finally, local phylo-
genetic analysis of clinical specimens may provide public
health with additional tools for outbreak investigations.
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